ANGES, VICAL TO COLLABORATE ON MELANOMA THERAPY
Japan-based AnGes has signed a collaboration agreement with U.S. company Vical for Allovectin-7, Vical's proprietary immunotherapeutic for malignant melanoma.
Allovectin-7 (A-7), which consists of a DNA plasmid, can induce tumor immunity, suppressing the growth of cancer.
Under the agreement terms, AnGes will support Phase III clinical trials while receiving the right to develop and market A-7 in Asia. In addition, the partners have concluded a strategic agreement under which AnGes will offer Vical $22.6 million for Phase III clinical trials.